22,001 Shares in Progyny, Inc. (NASDAQ:PGNY) Purchased by Guidance Capital Inc.

Guidance Capital Inc. purchased a new stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 22,001 shares of the company's stock, valued at approximately $380,000.

Several other institutional investors and hedge funds also recently made changes to their positions in PGNY. GAMMA Investing LLC lifted its position in shares of Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares in the last quarter. Creative Planning raised its stake in shares of Progyny by 13.8% during the 2nd quarter. Creative Planning now owns 10,564 shares of the company's stock valued at $302,000 after purchasing an additional 1,283 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares in the last quarter. Cetera Trust Company N.A boosted its stake in Progyny by 30.0% in the 3rd quarter. Cetera Trust Company N.A now owns 7,210 shares of the company's stock worth $121,000 after purchasing an additional 1,665 shares during the period. Finally, KBC Group NV grew its holdings in Progyny by 84.6% during the 4th quarter. KBC Group NV now owns 4,669 shares of the company's stock valued at $81,000 after buying an additional 2,140 shares in the last quarter. Institutional investors own 94.93% of the company's stock.

Progyny Stock Up 0.4 %

Shares of NASDAQ PGNY traded up $0.09 during trading hours on Friday, reaching $21.92. 1,557,297 shares of the stock traded hands, compared to its average volume of 1,883,574. The company has a market capitalization of $1.87 billion, a P/E ratio of 37.79, a price-to-earnings-growth ratio of 2.18 and a beta of 1.34. The company's 50-day simple moving average is $18.34 and its two-hundred day simple moving average is $18.96. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $286.63 million for the quarter, compared to analysts' expectations of $296.85 million. During the same period last year, the business posted $0.16 earnings per share. The company's revenue was up 2.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Canaccord Genuity Group lowered their target price on shares of Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a research note on Wednesday, November 13th. Barclays reduced their price target on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Truist Financial reiterated a "hold" rating and issued a $19.00 price objective (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Finally, Bank of America reduced their target price on Progyny from $22.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $25.50.

Insider Buying and Selling at Progyny

In other news, Chairman David J. Schlanger purchased 150,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was bought at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares of the company's stock, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Peter Anevski purchased 209,500 shares of the company's stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the transaction, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.